Filler Swelling After an Illness: When to Contact the Treating Clinician

The Short Answer: Recognized, Uncommon, and Usually Manageable

Sudden tenderness, firmness, or swelling where dermal filler was placed weeks or months earlier is unsettling, especially when it shows up during or just after a cold, the flu, a fever, COVID-19, or a vaccination. The useful question is not whether the filler has “failed.” It is which of three actions fits what you can see today: a routine call to the treating clinician, same-day contact with that clinician, or emergency services. The U.S. Food and Drug Administration names illness-related inflammation among the less-common risks of dermal fillers. Small published series describe firm, painful redness at previously filled sites in the days after a flu-like illness. In those reports, clinicians treated most reactions, and some milder episodes settled without a procedure. That is not the same thing as proof that the illness caused the swelling, and it is not an automatic emergency.

The FDA’s consumer update on dermal fillers states the less-common risk in these words: “Inflammation such as swelling or redness may develop near the dermal filler injection site following viral or bacterial illnesses or infections, vaccinations, or dental procedures.” The same page says most side effects, such as swelling and bruising, occur shortly after injection and many resolve in a few days to weeks, and that “in some cases, side effects may emerge weeks, months, or years later.” The most serious risk it names is accidental injection into a blood vessel, which can cause skin necrosis, stroke, or blindness. That is an injection-time injury. It is a different problem from swelling that begins months later during an illness. The page also tells readers they can report a problem with a dermal filler to MedWatch, the FDA safety information and adverse event reporting program.

Use the pattern in front of you, not a guess about the mechanism, to choose the first call:

• Routine call: Mild swelling that tracks the illness and starts to settle as you recover can wait for a non-urgent call or message to the clinic that treated you, so the episode is in the chart. This is a pattern, not a timed clearance. No study defines how many days of mild swelling are safe to watch.

• Same-day clinician contact: New or worsening pain, redness, warmth, firm lumps, one-sided or spreading swelling, fever, or swelling that persists or keeps growing after the illness has eased should go to the treating clinician the same day. If you cannot reach that clinic, a physician who can examine filler complications — commonly dermatology or plastic surgery — is the next call. Do not start leftover antibiotics or steroid tablets while you wait.

• Emergency services: Throat or tongue swelling, tightness in the throat, trouble breathing or swallowing, shortness of breath, a weak pulse, or feeling faint is an emergency. In the United States, call 911. Do not spend that time on a clinic callback. The American Academy of Allergy, Asthma & Immunology says throat swelling can be life-threatening and requires immediate medical attention. The American College of Allergy, Asthma & Immunology lists shortness of breath, tightness in the throat, trouble breathing or swallowing, and a weak pulse among severe symptoms that need immediate action.

The evidence behind this pattern is thin, and this article keeps it that way. A 2025 systematic review found six studies — four case series and two case reports — describing 25 women aged 22 to 65. There is no incidence rate, no male series, and no Fitzpatrick skin-type breakdown. In a 2017 five-patient series, the author wrote that a flu-like illness shortly before the swelling “may be coincidental.” Temporal clustering is not causation.

Why an Illness Is a Reported Trigger, Not a Proven Cause

A cold, influenza, COVID-19, a vaccine, or a short gastrointestinal illness can line up with swelling in the cheeks, lips, or tear troughs months after an uneventful filler visit. The 2024 CARE consensus, published in Dermatology and Therapy, treats that timing as a correlation reported in the literature, not as a completed causal proof. CARE is a four-person European expert board established by the filler manufacturer Teoxane. It is a consensus, not a controlled trial.

Most of the reported cases involve cross-linked hyaluronic acid. The 2017 series notes that the products it discussed were non-animal hyaluronic acid cross-linked with 1,4-butanediol diglycidyl ether, and that manufacturing methods differ and are partly confidential. The 2019 series says the hyaluronic acid molecule itself is not usually considered an immunogen, that added cross-linkers might be, and that it is difficult to conclude that one filler technology is more prone to these reactions than another.

CARE agreed on three hypotheses for late-onset reactions. The authors say the cause in any one person is likely to be a mix, and they do not claim a patient can tell the hypotheses apart at home:

1. Filler structure and breakdown products. CARE’s first hypothesis is that the gel’s physical and chemical structure, especially low-molecular-weight hyaluronic acid fragments produced as the gel breaks down, may trigger an immune response. The 2019 series discusses an earlier version of that idea and says whether those fragments are actually proinflammatory is still debated. Neither paper assigns the reaction to a named interleukin, a named Toll-like receptor, or a fixed month range of gel breakdown.

2. Infection introduced at injection, or a biofilm. CARE’s second hypothesis is bacteria introduced during injection, or a dormant biofilm that later provokes inflammation. That remains a hypothesis for some late reactions. It is not a diagnosis you can make from a mirror. When infection is the working concern, CARE’s pattern is different from a multi-site immune reaction: more often one site, one side, and sometimes an abscess.

3. A change in the host immune response. CARE’s third hypothesis is an immune-system shift, including viral illness or vaccination, that prolongs a foreign-body response or a delayed type IV (T-cell) reaction. The same paper notes that a pure type IV explanation does not fit every case: some inflammatory reactions do not return when corticosteroid treatment ends, even if the filler was not dissolved.

Across the consensus and the case series, the events named alongside late swelling are reported triggers. They are not proven causes:

• Flu-like illness. Fever, headache, sore throat, cough, and fatigue appear in the 2019 series a few days before facial swelling. CARE lists viral or flu-like illness among factors correlated with late-onset reactions.

• COVID-19 infection or vaccination, and some other vaccines. The 2025 review gathered reports after viral infection or COVID-19 vaccination. CARE also cites reports after COVID-19, influenza, and chickenpox vaccines. For COVID-19 vaccines, CARE describes a proposed mechanism in the papers it cites: spike-protein exposure blocking ACE2 at the implant site and producing local inflammation. That is a hypothesis attached to those reports, not a finding that every post-vaccine swelling works this way.

• Dental procedures. CARE lists recent dental treatment among patient factors, because dental work can seed bacteria. Scheduling rules for dental care and filler belong in the site’s guide to when to schedule dental work around dermal fillers. This article does not restate that interval.

• Trauma and nearby procedures. CARE lists procedure-related trauma among risk factors and advises patients, after injection, to avoid facial massage, laser treatment, radiofrequency, and ultrasound facial therapy. Those are prevention statements from the consensus, not evidence that a laser visit caused a specific late swelling.

CARE also cites an observation, from another report, that up to 71% of late-onset reactions occurred between September and December, and the authors treat that as a suggested seasonal pattern during the northern-hemisphere respiratory season. It is not a CARE patient registry, and it does not show that a winter virus caused any one person’s swelling.

What the Published Case Series Actually Documented

Three publications carry almost all of the patient-level detail: a 14-patient series from 2019, a 5-patient series from 2017, and a 2025 systematic review that pools them with four smaller reports. The treatments below are what clinicians did in those reports. They are not a home regimen.

The Turkmani et al. (2019) 14-Patient Series

The largest series focused on this timing is Turkmani, De Boulle, and Philipp-Dormston, Clinical, Cosmetic and Investigational Dermatology, 2019. The methods describe 14 women, ages 22 to 65, seen at two dermatology clinics between September 2016 and September 2018.

• What the chart showed. The methods text says each patient had received 2 to 6 hyaluronic acid treatments over the prior four years. Table 1 in the same paper lists one patient with 8 treatments, so the paper is internally inconsistent on that count. The last injection was 2 to 10 months before the reaction. Brands named in the table include Juvéderm, Teosyal, Belotero, Restylane, Surgiderm, and Hylaform. The authors say it is difficult to conclude that one technology is more prone than another.

• Timing. In all 14 cases as described in the methods, localized redness and firm, painful swelling started 3 to 5 days after an influenza-like illness (fever, headache, sore throat, cough, and fatigue). That is a range, not an average, and it is not a rule for the next patient.

• Where it swelled. The most common sites were the cheeks (9), tear troughs (8), and lips (3). The discussion says the majority reacted at all previously injected sites at the same time. One patient reacted on only one side of the face.

• What clinicians did. Patients received oral prednisolone or methylprednisolone. At a two-week follow-up, 10 of 14 had complete resolution on that steroid course. The other 4 still had minimal swelling, which was treated with hyaluronidase about one month after onset. The paper does not separately prove that the hyaluronidase, rather than time or the earlier steroid, cleared those four. Doses from the paper are omitted here on purpose: they are not instructions.

• Follow-up, and a counting problem. Two months after resolution, the authors write that patients experienced another influenza-like infection or a recurrence of symptoms at the filler sites. The “or” matters: the sentence does not establish that every patient both caught another illness and swelled again. Later in the discussion the authors say they present 10 rare cases, while the methods and Table 1 describe 14. Biopsies were not done. One coauthor discloses advisory or speaking roles for Allergan, Galderma, and Merz, and the paper says there was no payment for this publication.

The Bhojani-Lynch (2017) 5-Patient Series

Bhojani-Lynch, Plastic and Reconstructive Surgery – Global Open, 2017, reported five women with late inflammatory swelling after hyaluronic acid filler. The author is a consultant for Merz and Teoxane, and Merz paid the article processing charge. Read the clinical detail with that disclosure in view.

• Latency. Inflammation appeared at least 3 months after an uneventful injection, usually at 4 to 5 months, and in one patient almost 14 months later. The late case was limited to the lid-cheek area. The author notes that filler in the tear trough may degrade more slowly than filler elsewhere, which is an explanation offered for that case, not a rule for every under-eye treatment.

• Illness or gastrointestinal upset. Four of the five patients reported a flu-like illness or gastrointestinal upset a few days to about a week before the swelling. One of them later had a second, milder flare in the same facial areas after another gastrointestinal upset. Her lips, treated the same day with a different brand, stayed quiet both times. The author treats that single comparison as a hint that manufacturing differences might matter, and also writes that manufacturing details are confidential, so the hint is speculation.

• Antihistamines. Several patients took oral antihistamines without resolution. One patient who declined steroids improved over about two weeks while taking antihistamines; the author does not treat that recovery as evidence that antihistamines work, and writes that type IV reactions are unresponsive to antihistamines. The practical point for a reader is narrower: do not rely on an antihistamine to settle painful red filler swelling, and do not treat failure of an antihistamine as a diagnosis.

• Steroids, hyaluronidase, and massage. Where the author used a short oral prednisolone taper, inflammatory signs resolved. One persistent lump was injected with hyaluronidase. One patient massaged a swollen corner of the mouth before she was seen; the author writes that manipulation increased tenderness and edema. That is one patient, not a series. The author also writes that if infection is suspected, steroids should not be prescribed.

The Bhatia et al. (2025) Systematic Review

Bhatia and colleagues, Medicina, 2025, registered a systematic review (PROSPERO CRD420251030918) of delayed inflammation after hyaluronic acid filler associated with viral infection or COVID-19 vaccination. Searches ran in October and November 2024. Only case reports and case series were eligible.

• What qualified. Six publications met the criteria: four case series and two case reports, describing 25 women aged 22 to 65. The authors say there are no prospective or controlled studies.

• Onset. The abstract summarizes onset as several hours to several weeks after viral exposure. In the included reports, the documented span runs from 12 hours to six weeks. That spread is a reason not to treat “day 3 to day 5” as a requirement.

• What it looked like. Presentations included swelling, redness, angioedema, and, in severe reports, marked facial edema. The review does not sort these into a benign-versus-emergency score a patient can apply alone.

• What clinicians used. Corticosteroids and hyaluronidase were the most common treatments in the reports. Some milder cases resolved without an intervention. The authors say management was inconsistent and that there is no standardized guideline.

• Study quality. Quality on the Newcastle–Ottawa Scale varied. The review’s own bands treat 7–9 as higher quality, 4–6 as moderate, and 0–3 as high risk of bias. Two reports scored 7. The Turkmani series scored 3. The authors still call every conclusion preliminary and hypothesis-generating, because the entire set is case reports and case series.

The following evidence table consolidates the primary literature examining post-illness filler swelling:

Four Clinical Presentations of Delayed Swelling: Differentiating the Diagnoses

Swelling at an old filler site is not one diagnosis. The CARE consensus separates patterns that tend to look immune-mediated from patterns that tend to look infectious, and allergy organizations separately define airway angioedema. A fourth, milder pattern — puffiness that simply tracks the illness — is a clinical description used for triage. It is not a category the 2025 review measured. None of these rows is a home diagnosis.

1. Benign Transient Reactive Edema

Some swelling is soft, not very painful, not red, and not hot, shows up while the illness is active, and recedes as the illness recedes. Hyaluronic acid holds water, so a systemic illness that shifts fluid could make a stable gel look fuller. That is an inference, not a result from these studies. The review did not define this pattern, did not show it is the most common outcome, and did not name a number of days that proves the swelling is harmless. Pain, redness, warmth, a lump, one-sided swelling, or swelling that is still building after the illness eases does not fit this description.

2. Delayed Inflammatory Reaction

In the Turkmani methods, firm, painful redness began 3 to 5 days after the flu-like illness, often at more than one previously filled site, months after the last injection. Bhojani-Lynch described diffuse red, tender swelling and classified those cases as type IV hypersensitivity, which that paper says does not respond to antihistamines. CARE says immune-mediated late reactions tend to affect multiple filled sites and to show redness, warmth, and pain, while infection tends to be single-site or one-sided, sometimes with an abscess. Multi-site painful redness is a reason to contact the treating clinician the same day. It is not a reason to start a steroid at home, and antihistamine failure does not prove the label.

3. Suspected Bacterial Infection

CARE’s infection pattern is the one that should not be watched as “just the cold.” It tends to be one site or one side, and it may form an abscess. The consensus says the clinician should drain and culture a suspected infection rather than dissolve the filler: hyaluronidase may spread the infection further and should be avoided. CARE does not recommend hyaluronidase as first-line treatment for infection. In the consensus, a fluctuant collection is drained and cultured by the clinician, a nonfluctuant nodule may be biopsied and cultured, and antibiotics are that clinician’s choice while results are pending. Fever can occur with infection, but fever during the original viral illness does not by itself prove a filler abscess. The person who can make that distinction is the clinician examining you, not a checklist.

4. Acute Angioedema vs. Vascular Occlusion

Two further problems are easy to mix into this story, and they do not belong in the same action:

• Angioedema. The AAAAI describes angioedema as swelling below the surface of the skin and fatty tissue, usually in the face, throat, hands, and feet. It can be painful, it can occur with or without hives, and it is a medical term for swelling rather than a single disease. The AAAAI’s sentence for emergencies is specific: throat swelling can be life-threatening and requires immediate medical attention. The same page says to talk to a doctor if swelling occurs without hives, because that may be a situation that needs more evaluation. The AAAAI page is not about dermal fillers. It is used here only for the swelling definition and the throat-swelling threshold. Trouble breathing or swallowing, shortness of breath, and a weak pulse are the severe-symptom language on the ACAAI epinephrine page, which is about anaphylaxis generally, not about filler.

• Injection into a blood vessel. The FDA calls accidental injection into a blood vessel the most serious dermal-filler risk, because filler in a vessel can cause skin necrosis, stroke, or blindness. That injury is tied to the injection. The illness series describes swelling that began months after treatment, which is a different problem. Warning signs and timing for vascular occlusion are covered in the site’s patient guide to dermal filler complications. How those events show up in FDA reports is covered in the analysis of more than 22,000 dermal-filler MAUDE reports.

The following matrix compares these four clinical entities across key diagnostic parameters:

When to Contact Your Treating Clinician vs. When to Seek Emergency Care

The decision is who to contact, and how fast. The rows below use the AAAAI and ACAAI emergency language and the CARE pattern split. They are not a score, and they do not authorize a medication.

Tier 1: Routine Follow-Up and Home Monitoring

A routine call fits only when every part of this description is true:

• The swelling is mild and soft, without a new hard lump.

• Pain is absent or limited to mild tightness. There is no throbbing pain.

• The skin is not red and not hot compared with nearby skin.

• The change began with the viral illness and is stabilizing or easing as the illness eases.

The AAAAI says, “Talk to your doctor if swelling occurs without hives,” because swelling without hives may need more evaluation. That sentence is not a filler rule, and it does not set a 24-hour or 48-hour deadline. If the description above fits and there is no throat, breathing, or pulse emergency, call or message the treating clinic during ordinary hours so the episode is recorded. If you are unsure the description fits, use the same-day path.

Tier 2: Same-Day Contact with the Treating Clinician

Contact the treating clinician the same day if any of these are present:

• Pain that is new or worsening. Aching or throbbing at the filler site beyond mild fullness.

• Redness or heat. Skin over the area is clearly redder or warmer than nearby skin.

• A new lump. A firm nodule or a hard area that was not part of the settled filler result.

• One-sided or spreading swelling. One cheek, one side of the lip, or one tear trough changes while other treated areas stay quiet. CARE treats a single-site, one-sided pattern as the infection side of the split.

• Fever that does not belong to the original illness. Fever, chills, or a clear worsening after the cold or flu has already turned the corner. Fever during the viral illness itself is not, by itself, a filler abscess.

• Swelling that outlasts the illness. The area keeps enlarging, spreads past the treated zone, or is still building after the systemic illness has eased. No source reviewed here defines a safe number of days to wait once that happens.

The treating clinician is the right first call because the chart holds the product, the date, the depth, and the volume. CARE’s management split is a clinician’s split: watchful waiting and/or a tapered oral steroid for inflammatory reactions, hyaluronidase considered earlier for noninflammatory nodules, and drainage plus culture instead of hyaluronidase when infection is suspected. The consensus also says to refer to a dermatologist or local expert if symptoms persist after those interventions. Your call is to get that assessment. It is not a request for a specific prescription by phone, and it is not permission to use tablets left over from another illness.

Tier 3: Immediate Emergency Services (Call 911)

Stop and contact emergency services if any of the following is happening. The throat-swelling line is the AAAAI’s. The breathing, swallowing, and pulse lines are the ACAAI’s severe-symptom list. Tongue swelling and feeling faint are included because they are the same airway and circulation emergency, not because either organization wrote a filler protocol.

• Throat swelling, or swelling of the tongue that makes the airway feel tight.

• Tightness in the throat, trouble breathing, or trouble swallowing.

• Shortness of breath.

• A weak pulse, or feeling faint.

• In the United States, the emergency number is 911. The cited allergy pages say to get immediate medical attention; they do not name a clinic callback as a substitute.

The following clinical decision table summarizes the symptom thresholds, urgency levels, and required actions:

The chart below is the same choice in order: emergency symptoms first, then same-day clinician contact, then a routine call. It stops at who to contact. It is not a steroid, antibiotic, or hyaluronidase protocol.

flowchart TD
    Start["Swelling at a previously filled site during or after an illness"] --> Airway{"Throat or tongue swelling, trouble breathing or swallowing, shortness of breath, a weak pulse, or feeling faint?"}
    Airway -->|Yes| Emergency["Contact emergency services now"]
    Airway -->|No| Flags{"Pain, redness, warmth, a new lump, one-sided or spreading swelling, or swelling that persists or worsens after the illness eases?"}
    Flags -->|Yes| SameDay["Contact the treating clinician the same day"]
    Flags -->|No| Mild{"Mild, soft swelling that is tracking the illness and settling as you recover?"}
    Mild -->|Yes| Routine["Routine call or message to the treating clinic"]
    Mild -->|No| SameDay

What to Prepare Before Contacting Your Clinician

A prepared history helps the clinician separate a multi-site inflammatory pattern from a single-site infection. It does not replace the exam.

Five facts are worth having before the call:

1. Product name and lot number, if you have them. The 2019 table lists several hyaluronic acid brands, and the authors say it is difficult to conclude that one technology is more prone to this reaction. The 2017 series includes one patient who swelled at sites treated with one brand and not at sites treated the same day with another; the author treats that as a hint, not a rule. Tell the clinician the product. Do not decide from a brand nickname that the swelling is or is not serious. If the clinic holds the lot number, ask for the treatment record. The site’s guide to requesting aesthetic treatment records, device settings, and lot numbers covers what to ask for and what a clinic is not required to create.

2. Illness dates. When symptoms started, whether there was a fever, the day you first noticed facial swelling, and whether the face changed during the fever or several days later. The 3-to-5-day gap is what the 2019 methods describe. It is not a test you pass or fail.

3. Daily photos. The same lighting, the same angles, no smoothing filter. A series shows whether the area is spreading, settling, or gathering into a lump. A single filtered selfie does not.

4. Medicines and recent vaccines. Antihistamines, anti-inflammatory pain medicines, antibiotics, and any vaccine in the previous weeks. Write down what you already took. Do not add a leftover antibiotic or steroid to the list by taking it now.

5. Whether this has happened before. A prior episode after an illness, a vaccine, or dental work is relevant history. Recurrence was seen in the two series and was not counted, so a prior episode does not prove the next one, and a first episode does not prove there will never be another.

Recurrence, Hyaluronidase Dissolving, and Future Aesthetic Planning

After the swelling settles, the next questions are whether it will return with the next cold, whether dissolving the gel prevents that, and whether another filler treatment is a settled “yes” or “no.” The sources answer those questions only in part.

Understanding Recurrence Risk

Turkmani’s follow-up sentence says patients experienced another influenza-like infection or a recurrence of symptoms at the filler sites. It does not report a rate. Bhojani-Lynch describes one patient whose face flared a second time, more mildly, after another gastrointestinal illness, in the areas treated with one brand and not in the lips treated with the other. Recurrence can happen. These papers do not say how often, and they do not show that a primed immune system makes another episode inevitable.

The Role of Hyaluronidase in Refractory Cases

In the 2019 series, 4 of 14 patients still had minimal swelling after the oral steroid course and were treated with hyaluronidase about a month after onset. The paper does not isolate that injection as the proven reason those four cleared. CARE’s split is more specific than “always dissolve”: hyaluronidase is a reasonable first step for noninflammatory nodules, watchful waiting and/or a tapered oral steroid is preferred for inflammatory reactions so hyaluronidase is not used unnecessarily, and hyaluronidase should be avoided when infection is suspected because it may spread the infection. How dissolution is done, including ultrasound and allergy considerations, is covered in the guide to dissolving filler with hyaluronidase. Movement of filler away from the injected site is a different problem, covered in the guide to filler migration.

Nothing in these sources shows that dissolving the current gel prevents a reaction if new filler is placed later. Dissolving removes a deposit that is already inflamed. It does not answer whether the next treatment is wise.

Before the Next Treatment: What These Sources Do Not Establish

CARE says a filler treatment should be delayed or canceled when the patient has an active systemic or skin infection, has recently had a dental procedure, or has certain other active inflammatory problems. That is a clinician’s scheduling judgment at the time of a new injection. It is not a studied waiting period after an ordinary cold, and it is not a vaccine-interval rule. The September 2026 Journal of Drugs in Dermatology consensus (Cohen and colleagues) reached full agreement on eight recommendations across patient history, product characteristics, technique, and aftercare, and it states that many current guideline recommendations lack robust evidence. The public abstract does not list the eight recommendations. This article does not invent them.

• An active infection is a reason CARE gives to delay or cancel filler. A cold that has already resolved does not come with a two-week or four-week rule in the sources read for this article. Do not treat a number of weeks you saw on social media as guidance from CARE or from the 2026 consensus.

• Dental timing stays in one place. Recent dental treatment is a named risk context in CARE. The interval discussion, including emergency dental care that cannot wait, is in the guide to dental procedures and dermal filler timing. This article does not add a second calendar.

• A prior reaction does not create a product rule. Turkmani cautions against concluding that one technology is more prone. Bhojani-Lynch’s two-brand case is a single observation. Changing product or stacking brands is a decision for the treating clinician with your record in hand, not a step these papers establish.

Evidence Limitations, Open Questions, and What Remains Unknown

The phenomenon is documented well enough for the FDA to name it and badly enough that no one can tell you the chance it will happen to you. The limits below are part of the answer, not an appendix.

Methodological Vulnerabilities in the Current Literature

1. Twenty-five published patients. The 2025 review’s entire set is 25 women in six retrospective reports. There is no prospective cohort, no randomized trial, and no population rate. A sentence such as “1 in 1,000” or “1 in 100,000” would be invented. This article does not use one.

2. Bias is uneven, and the design is weak throughout. Case reports over-represent dramatic episodes. On the review’s Newcastle–Ottawa scoring, two reports scored 7 and the Turkmani series scored 3 out of 9, which the review calls high risk of bias. The authors also note that the scale was built for observational studies and fits this literature poorly. Separate from the score, Turkmani’s methods say 14 patients and the discussion says 10, and the methods’ treatment count does not match Table 1 for every row. No biopsies were done in that series.

3. No men and no older-age series. All 25 patients in the review were women aged 22 to 65. The papers do not support a statement about how this looks in men or in older patients.

4. No skin-type data. None of the illness-triggered series report Fitzpatrick phototype or a racial or ethnic breakdown. CARE lists postinflammatory hyperpigmentation among late-onset reaction types in general. That listing is not a measured risk for Fitzpatrick IV–VI after illness-related filler swelling, and this article does not estimate one.

5. Industry relationships. CARE was established by Teoxane. The paper says the authors received no payment for the research itself and that Teoxane paid the open-access fee. All four authors disclose Teoxane consulting roles. Bhojani-Lynch discloses consulting for Merz and Teoxane, and Merz paid that article’s processing charge. Turkmani’s coauthor Philipp-Dormston discloses advisory or speaking roles for Allergan, Galderma, and Merz, with no payment stated for that publication. Consensus and case series with those ties are still citable. They are not independent trials.

6. The 2026 consensus does not fill the gap. Cohen and colleagues, Journal of Drugs in Dermatology, September 2026, report full agreement among eight U.S. injectors on eight recommendations in four categories: patient history, product characteristics, technique, and post-procedure care. The abstract’s own theme is that many current recommendations lack robust evidence. The full text was not available through the Duke Scholars record used here, so the eight recommendations are not quoted.

Key Unanswered Clinical Questions

These questions stay open because the sources do not answer them:

• How long may mild swelling be watched? CARE allows watchful waiting for some inflammatory reactions. No study defines the day on which a mild, settling swelling must be seen in person. This article therefore does not use a seven-day or a 48-hour cutoff.

• Does one episode predict the next? Recurrence appears in both small series and is not given a probability.

• Does dissolving the gel prevent a later episode? Dissolving was used for persistent swelling. Prevention of a future reaction after new filler was not studied.

• How should a new filler visit be timed around illness or vaccination? CARE says to delay or cancel treatment during active infection, and it cites vaccine-associated reports. It does not supply a tested number of weeks after a cold or after a vaccine. Dental intervals are handled in the linked dental-timing article, not here.

• Does risk differ by skin type, brand, or facial site? Skin type is unreported. Brand comparisons are speculation plus one two-product case. The only site counts in the 2019 series are cheeks 9, tear troughs 8, and lips 3, which describe where those 14 patients swelled, not where swelling is most dangerous.

The Role of FDA MedWatch Reporting

The FDA consumer page says that if you have a problem with a dermal filler, or with another FDA-regulated product, you can voluntarily report it to MedWatch. A report is a safety signal to the agency. It is not a substitute for the call this article is about, and it is not a claim that the agency will diagnose the swelling. The MedWatch route is the reporting path named on the FDA page cited in Sources.

Sources

1. U.S. Food and Drug Administration (FDA). Dermal Filler Do's and Don'ts for Wrinkles, Lips and More (FDA Consumer Update). https://www.fda.gov/consumers/consumer-updates/dermal-filler-dos-and-donts-wrinkles-lips-and-more

2. Turkmani MG, De Boulle K, Philipp-Dormston WG. Delayed hypersensitivity reaction to hyaluronic acid dermal filler following influenza-like illness. Clin Cosmet Investig Dermatol. 2019;12:277–283. https://pmc.ncbi.nlm.nih.gov/articles/PMC6501047/

3. Bhojani-Lynch T. Late-Onset Inflammatory Response to Hyaluronic Acid Dermal Fillers. Plast Reconstr Surg Glob Open. 2017;5:e1532. https://pmc.ncbi.nlm.nih.gov/articles/PMC5889432/

4. Bhatia L, Al Rekabi S, Janovskiene A, et al. Systematic Review of Post-Viral Delayed Inflammation Associated with Hyaluronic Acid Dermal Fillers. Medicina (Kaunas). 2025;61(10):1764. https://pmc.ncbi.nlm.nih.gov/articles/PMC12565858/

5. Baranska-Rybak W, Lajo-Plaza JV, Walker L, Alizadeh N. Late-Onset Reactions after Hyaluronic Acid Dermal Fillers: A Consensus Recommendation on Etiology, Prevention and Management. Dermatol Ther (Heidelb). 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11265052/

6. Cohen JL, Woodward J, Barbarino S, et al. Risk Factors Associated With Hyaluronic Acid Filler-Related Delayed Complications: A Literature Review and Expert Consensus. J Drugs Dermatol. 2026;25(9):785–792. https://scholars.duke.edu/publication/1918636

7. American Academy of Allergy, Asthma & Immunology (AAAAI). Hives (Urticaria) & Angioedema — Symptoms, Diagnosis & Treatment (AAAAI Conditions Library). https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/hives-(urticaria)-and-angioedema-overview

8. American College of Allergy, Asthma & Immunology (ACAAI). Epinephrine Auto Injector — Symptoms & Treatment. https://acaai.org/allergies/management-treatment/epinephrine-auto-injector